Microba Life Sciences Limited

DB:F3Y Stock Report

Market Cap: €30.7m

Microba Life Sciences Management

Management criteria checks 1/4

Microba Life Sciences' CEO is Luke Reid, appointed in Jul 2021, has a tenure of 4.17 years. total yearly compensation is A$671.57K, comprised of 52.1% salary and 47.9% bonuses, including company stock and options. directly owns 0.084% of the company’s shares, worth €25.73K. The average tenure of the management team and the board of directors is 1.7 years and 2.8 years respectively.

Key information

Luke Reid

Chief executive officer

AU$671.6k

Total compensation

CEO salary percentage52.06%
CEO tenure4.2yrs
CEO ownership0.08%
Management average tenure1.7yrs
Board average tenure2.8yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Luke Reid's remuneration changed compared to Microba Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$672kAU$350k

-AU$15m

Mar 31 2025n/an/a

-AU$15m

Dec 31 2024n/an/a

-AU$14m

Sep 30 2024n/an/a

-AU$17m

Jun 30 2024AU$567kAU$310k

-AU$20m

Mar 31 2024n/an/a

-AU$19m

Dec 31 2023n/an/a

-AU$18m

Sep 30 2023n/an/a

-AU$16m

Jun 30 2023AU$382kAU$278k

-AU$13m

Mar 31 2023n/an/a

-AU$12m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$407kAU$248k

-AU$11m

Mar 31 2022n/an/a

-AU$11m

Dec 31 2021n/an/a

-AU$11m

Sep 30 2021n/an/a

-AU$9m

Jun 30 2021AU$268kAU$144k

-AU$8m

Compensation vs Market: Luke's total compensation ($USD440.00K) is about average for companies of similar size in the German market ($USD504.49K).

Compensation vs Earnings: Luke's compensation has increased whilst the company is unprofitable.

CEO

Luke Reid

4.2yrs
Tenure
AU$671,566
Compensation

Dr. Luke Reid is Chief Executive Officer of Microba Life Sciences Limited from July 15, 2021. He is an experienced research and technology commercialisation executive. His deep knowledge of the biotechnolo...

Leadership Team

NamePositionTenureCompensationOwnership
Luke Reid
Chief Executive Officer4.2yrsAU$671.57k0.084%
€ 25.7k
Gene Tyson
Co-Founder & Non-Executive Directorno dataAU$115.80k2.61%
€ 801.3k
James Heath
CFO & Company Secretaryno dataAU$407.39k0.087%
€ 26.8k
Philip Hugenholtz
Co-Founder & Chair of Scientific Advisory Boardno datano datano data
Bernie Woodcroft
Chief Operating Officer1.7yrsno datano data
David Wood
Chief Technology Officer1.7yrsno datano data
Lutz Krause
Chief Scientific Officerno datano datano data
Drew Webb
Chief Marketing Officerno datano datano data
Trent Munro
Senior Vice President of Therapeuticsno datano datano data
Nicola Angel
Head of Laboratory Operationsno datano datano data
Hayley Parcell
Head of Co-Biome Healthcareno datano datano data
1.7yrs
Average Tenure

Experienced Management: F3Y's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Gene Tyson
Co-Founder & Non-Executive Directorno dataAU$115.80k2.61%
€ 801.3k
Philip Hugenholtz
Co-Founder & Chair of Scientific Advisory Boardno datano datano data
Pasquale Rombola
Independent Non-Executive Chairmanno dataAU$106.70k1.08%
€ 330.7k
Ian Frazer
Independent Non-Executive Deputy Chairman of the Board & Chair of Medical Advisory Boardno dataAU$96.70k0.44%
€ 134.3k
Jacqueline Fernley
Independent Non-Executive Director3yrsAU$64.09kno data
Stephen Fairy
Member of Medical Advisory Board2.8yrsno datano data
Richard Bund
Non-Executive Directorno dataAU$77.80k5.5%
€ 1.7m
Hyungtae Kim
Non-Executive Directorno dataAU$57.80kno data
Paul Griffin
Member of Medical Advisory Boardno datano datano data
Jake Begun
Member of Medical Advisory Boardno datano datano data
Chris Hogan
Member of Medical Advisory Board2.8yrsno datano data
2.8yrs
Average Tenure

Experienced Board: F3Y's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/05 14:10
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Microba Life Sciences Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter
Thomas WakimBell Potter
Elyse ShapiroCanaccord Genuity